Cargando…
Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine
Vaccines are the most effective strategy to mitigate the global impact of COVID-19. However, vaccine hesitancy is common, particularly among minorities. Guillain-Barré syndrome (GBS) is the most common autoimmune illness of the peripheral nervous system, occurring at an incidence of 1.1/100,000 worl...
Autores principales: | García-Grimshaw, Miguel, Michel-Chávez, Anaclara, Vera-Zertuche, Juan Mauricio, Galnares-Olalde, Javier Andrés, Hernández-Vanegas, Laura E., Figueroa-Cucurachi, Melissa, Paredes-Ceballos, Orlando, Reyes-Terán, Gustavo, Carbajal-Sandoval, Guillermo, Ceballos-Liceaga, Santa Elizabeth, Arauz, Antonio, Valdés-Ferrer, Sergio Iván |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332675/ https://www.ncbi.nlm.nih.gov/pubmed/34358692 http://dx.doi.org/10.1016/j.clim.2021.108818 |
Ejemplares similares
-
Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study
por: García-Grimshaw, Miguel, et al.
Publicado: (2021) -
Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study
por: García-Grimshaw, Miguel, et al.
Publicado: (2021) -
Guillain-Barré syndrome following BNT162b2 COVID-19 vaccine
por: Trimboli, Michele, et al.
Publicado: (2021) -
Case report of Guillain-Barré Syndrome after COVID BNT162b2 mRNA vaccine()
por: Sosa-Hernández, Oscar, et al.
Publicado: (2022) -
Guillain–Barré syndrome associated with BNT162b2 COVID vaccination: a first case report from South Korea
por: Kim, Namkyun, et al.
Publicado: (2022)